Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02224599 · ClinicalTrials.gov registry record · Phase 1
Cyclophosphamide, TAPA-Pulsed Dendritic Cell Therapy and Imiquimod in Progressive and/or Refractory Solid Malignancies
A Phase 1 study, sponsored by Kiromic BioPharma.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT02224599: Clinical Trial Phase 1 study, sponsored by Kiromic BioPharma.
NCT02224599 is a Phase 1 study that was terminated before completion, run by Kiromic BioPharma. The registered enrollment target is 3 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02224599, a Phase 1 study, was terminated before completion, sponsored by Kiromic BioPharma.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
Patients diagnosed with progressive and/or refractory solid malignancies, who have failed conventional therapy, and have no available, potentially curative therapeutic options, will be candidates for this Phase I/II study. Following confirmation of disease progression and/or refractoriness, eligible patients who agree to participate and sign an informed consent form will have their tumor cells/tissues and/or blood analyzed for the expression of a specific panel of Tumor Associated Peptide Antigens (TAPAs), including Sp17, ropporin, AKAP-4, PTTG1, Span-xb, Her-2/neu, HM1.24, NY-ESO-1 and MAGE-1.
Primary Outcome
Grade, causality, start/stop dates (duration), resolutions for adverse events will be monitored and recorded.
Interventions
- DRUG Cyclophosphamide Pill
- BIOLOGICAL TAPA-pulsed DC vaccine
- DRUG Imiquimod Topical Cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2017-07-28 |
| Est. Completion | 2018-08-30 |
| Phase | Phase 1 |
Why NCT02224599 stopped before completion
NCT02224599 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 3 interventions - of which Cyclophosphamide Pill is the first listed.
NCT02224599 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02224599 about?
NCT02224599 is a clinical study titled "Cyclophosphamide, TAPA-Pulsed Dendritic Cell Therapy and Imiquimod in Progressive and/or Refractory Solid Malignancies". Patients diagnosed with progressive and/or refractory solid malignancies, who have failed conventional therapy, and have no available, potentially curative therapeutic options, will be candidates for this Phase I/II study. Following confirmation of disease progression and/or refractoriness, eligible...
What is the current status of trial NCT02224599?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2017-07-28. Estimated completion is 2018-08-30.
What interventions are being tested in trial NCT02224599?
The interventions under investigation include: Cyclophosphamide Pill (DRUG), TAPA-pulsed DC vaccine (BIOLOGICAL), Imiquimod Topical Cream (DRUG).
Who is sponsoring clinical trial NCT02224599?
This trial is sponsored by Kiromic BioPharma, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02224599's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI